Page de couverture de S2 Ep8: The FDA Decision for Pompe Disease Therapy

S2 Ep8: The FDA Decision for Pompe Disease Therapy

S2 Ep8: The FDA Decision for Pompe Disease Therapy

Écouter gratuitement

Voir les détails du balado

À propos de cet audio

The FDA is expected to announce the final decision for the dual therapy AT-GAA, which uses miglustat in combination with cipaglucosidase alfa for treating Pompe disease, an inherited and often times fatal disorder. Expert Barry Byrne discusses the characteristics of the condition and what this FDA decision will mean for treatment.

Ce que les auditeurs disent de S2 Ep8: The FDA Decision for Pompe Disease Therapy

Moyenne des évaluations de clients

Évaluations – Cliquez sur les onglets pour changer la source des évaluations.